PUBLICATIONS
Alzheimer’s Disease
New
Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies
Changyoun Kim, Armine Hovakimyan, Karen Zagorski, Tatevik Antonyan, Irina Petrushina, Hayk Davtyan, Gor Chailyan, Jonathan Hasselmann, Michiyo Iba, Anthony Adame, Edward Rockenstein, Marcell Szabo, Mathew Blurton-Jones, David H. Cribbs, Anahit Ghochikyan, Eliezer Masliah & Michael G. Agadjanyan 
npj Vaccines volume (2022)
1
Petrushina I, Hovakimyan A, Harahap-Carillo I, Davtyan H, Antonyan T, Chailyan G, Kazarian K, Antonenko M,Julienne A,Hamer MM, Obenaus A, King O, Zagorski K, Blurton-Jones M, Cribbs DH, Lander H, Ghochikyan A, Agadjanyan MG. Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-men clinical trials. Neurobiol Dis. 2020 Feb 28;139:104823. doi: 10.1016/j.nbd.2020.104823.
2
Davtyan H, Hovakimyan A, Kiani Shabestari S, Antonyan T, Coburn MA, Zagorski K, Chailyan G, Petrushina I, Svystun O, Danhash E, Petrovsky N, Cribbs DH, Agadjanyan MG, Blurton-Jones M, Ghochikyan A. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice. Alzheimers Res Ther. 2019 Dec 17;11(1):107. doi: 10.1186/s13195-019-0556-2.
3
Joly-Amado A, Davtyan H, Serraneau K, Jules P, Zitnyar A, Pressman E, Zagorski K, Antonyan T, Hovakimyan A, Paek HJ, Gordon M.N, Cribbs D.H, Petrovsky N, Agadjanyan M.G, Ghochikyan A, Morgan D. Active immunization with tau epitope in a mouse model of tauopathy induced a strong antibody response together with improvement in short memory and pSer396-tau pathology. Neurobiol Dis. 2020 Feb;134:104636. doi: 10.1016/j.nbd.2019.104636.
4
Hovakimyan A, Antonyan T, Shabestari SK, Svystun O, Chailyan G, Coburn MA, Carlen-Jones W, Petrushina I, Chadarevian JP, Zagorski K, Petrovsky N, Cribbs DH, , Agadjanyan MG, Ghochikyan A,Davtyan H. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice. Sci Rep. 2019 Oct 29;9(1):15455. doi: 10.1038/s41598-019-51809-2.
5
Davtyan H, Zagorski K, Petrushina I, Kazarian K, Goldberg NRS, Petrosyan J, Blurton-Jones M, Masliah E, Cribbs DH, Agadjanyan MG, Ghochikyan A. MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiol Aging. 2017 017 Nov; 59:156-170.
6
Agadjanyan MG, Zagorski K, Petrushina I, Davtyan H, Kazarian K, Antonenko M, Davis J, Bon C, Blurton-Jones M, Cribbs DH, Ghochikyan A. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency.Mol Neurodegener. 2017 May 5;12(1):33.
7
Davtyan H., Chen W.W., Zagorsky K., Davis J., Petrushina I., Kazarian K., Cribbs D.H., Agadjanyan M.G., Blurton-Jones M., Ghochikyan A. MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine, 2017, 35(16):2015-2024.
8
Petrushina I., Davtyan H., Hovakimyan A., Davtyan A., Passos G.F., Cribbs D.H., Ghochikyan A., Agadjanyan M.G. Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.Mol Ther. 2017 Jan 4;25(1):153-164.
9
Davtyan H., Zagorski K., Rajapaksha H., Hovakimyan A., DavtyanA., PetrushinaI., Kazarian K., Cribbs D.H., Petrovsky N., Agadjanyan M.G., GhochikyanA. Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules. Scientific Reports, 2016, 6:28912.
10
11
Davtyan H, Ghochikyan A, Hovakimyan A, Davtyan A, Cadagan R, Marleau AM, Albrecht RA, García-Sastre A, Agadjanyan MG. A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory. J Neuroimmunol. 2014 Dec 15;277(1-2):77-84.
12
Ghochikyan A, Pichugin A, Bagaev A, Davtyan A, Hovakimyan A, Tukhvatulin A, Davtyan H, Shcheblyakov D, Logunov D, Chulkina M, Savilova A, Trofimov D, Nelson EL, Agadjanyan MG, Ataullakhanov RI. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer. J Transl Med. 2014 Nov 29;12:322.
13
Davtyan H, Hovakimyan A., Zagorski K., Davtyan A., Petrushina I., Agdashian D., Murthy V., Cribbs D.H., Agadjanyan M.G., Ghochikyan A, BTX AgilePulseMT System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine. Curr Gene Ther. 2014;14(3):190-9.
14
Davtyan H, Petrushina I, Ghochikyan A. Immunotherapy for Alzheimer's disease: DNA- and protein-based epitope vaccines. Methods Mol Biol. 2014; 1143:259-81.
15
Davtyan H, Ghochikyan A, Petrushina I., Hovakimyan A., Davtyan A., Cribbs D.H., Agadjanyan M.G., MultiTEP platform-based AD epitope vaccine activates broad repertoire of T helper cells in non-human primates. Alzheimers Dement. 2014 May; 10(3):271-83.
16
Davtyan H., Ghochikyan A., Hovakimyan A., Petrushina I., Yu J., Flyer D., Madsen P.J., Pedersen L.O., Cribbs D.H., Agadjanyan M.G., Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. J Neuroimmunol.  2014 Mar 15; 268 (1-2):50-7.
17
Davtyan H., Bacon A., Petrushina I., Zagorski K., Cribbs D.H., Ghochikyan A., Agadjanyan M.G., Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease Epitope Vaccines. Hum Vaccin Immunother. 2014 Feb 13;10(5):1-8.
18
Ghochikyan A., Petrushina I., Davtyan H., Hovakimyan A., Saing T., Davtyan A., Cribbs D.H., Agadjanyan M.G., Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: Feasibility study. Neurosci Lett. 2014 Feb 7;560:86-91.
19
Evans C.F., Davtyan H, Petrushina I., Hovakimyan A., Davtyan A., Hannaman D., Cribbs D.H., Agadjanyan M.G., Ghochikyan A. Epitope-based DNA vaccine for Alzheimer’s disease: translational study in macaques. Alzheimers Dement. 2014 May;10(3):284-95.
20
Davtyan, H., Ghochikyan, A., Petrushina,I., Hovakimyan, A., Davtyan, A., Poghosyan, A., Marleau, A.M., Movsesyan, N., Kiyatkin, A., Rasool, S., Larsen, S.A., Madsen, P.J., Wegener, K.M., Ditlevsen, D.K., Cribbs, D.H., Pedersen, L.O., Agadjanyan, M.G. Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer’s Disease: Prelude to a Clinical Trial. J. Neuroscience 2013, Mar 13; 33(11):4923-34.
21
Ghochikyan A., Davtyan H., Petrushina, I, Hovakimyan, A., Movsesyan, N., Davtyan, A., Kiyatkin, A., Cribbs, D.H., Agadjanyan, M.G. Refinement of a DNA based Alzheimer’s disease epitope vaccine in rabbits, Hum Vaccin Immunother. 2013 Feb 11;9(5).
22
Davtyan H, Ghochikyan A, Cadagan R, Zamarin D, Petrushina I, Movsesyan N, Martinez-Sobrido L, Albrecht RA, García-Sastre A, Agadjanyan MG. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J Transl Med. 2011 Aug 1;9:127.
23
Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, Lobanenkov V, Cribbs DH, Laust AK, Nelson EL, Agadjanyan MG. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.
Cell Immunol. 2011, 270(2):188-97.
24
Robert R, Lefranc MP, Ghochikyan A,Agadjanyan MG, Cribbs DH, Van Nostrand WE, Wark KL, Dolezal O. Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide. Mol Immunol. 2010 Nov-Dec;48 (1-3):59-72.
25
Movsesyan N, Davtyan H, Mkrtichyan M, Petrushina I, Tiraturyan T, Ross TM, Agadjanyan MG, Ghochikyan A, Cribbs DH. Low concentrations of anti-Abeta antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. Hum Gene Ther., 2010, 21(11): 1569-1576.
26
Davtyan H., Mkrtichyan M., Movsesyan N., Petrushina I., Mamikonyan G., Cribbs DH., Agadjanyan MG., Ghochikyan A. DNA prime/protein boost increased the titer, avidity and persistence of anti-Ab antibodies in wild-type mice. Gene Therapy, 2010 Feb; 17, 261–271.
27
Ghochikyan A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets. 2009 Apr;8(2):128-43
28
Petrushina I., Ghochikyan A., Mkrtichyan M., Mamikonyan G., Movsesyan G., Ajdari R., Vasilevko V.,Karapetyan A., Lees A., Agadjanyan MG, Cribbs DH. Mannan-Ab28 conjugate prevented Ab-plaque deposition, but increased microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J.Neuroinflammation, 2008 Sep 29;5:42.
29
Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS ONE. 2008 May 7;3(5):e2124.
30
Mkrtichyan M, Ghochikyan A, Movsesyan N, Karapetyan A, Begoyan G, Yu J, Glenn GM, Ross TM, Agadjanyan MG, Cribbs DH. Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization. DNA Cell Biol. 2008 Jan;27(1):19-24.
31
Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci. 2007 Nov 14;27(46):12721-31.
32
Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, Movsesyan N, Mina E, Kiyatkin A, Glabe C, Cribbs DH, Agadjanyan MG. Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J Biol Chem. 2007 282:22376-86.
33
Ghochikyan, A., Petrushina, I., Lees, A., Vasilevko, V., Movsesyan, N., Karapetyan, A., Agadjanyan,M.G., Cribbs, D.H., Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates 2006. DNA Cell Biol. 2006, 25(10):571-80.
34
Ghochikyan A., Mkrtichyan M., Petrushina I., Movsesyan N., Karapetyan A., Cribbs D.H., Agadjanyan M.G. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.
Vaccine. 2006, 24(13):2275-82.
35
Agadjanyan M.G., Ghochikyan A., Petrushina I.. Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T., Cribbs D.H. Prototype Alzheimer's disease vaccine utilizing the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope PADRE. J Immunol. 2005, 174 (3):1580-6.
36
Gevorkian G., Petrushina I., Manucharian K., Ghochikyan A., Acero G., Vasilevko V., Cribbs D.H., Agadjanyan M.G. Mimotopes of conformational epitopes in fibrillar beta-amyloid. J. Neuroimmonol. 2004 256(1-2): 10-20.
37
Ghochikyan A., Vasilevko V., Petrushina I., Movsesyan N., Babikyan D., Tian W., Sadzikava N., Ross T., Head L., Cribbs D. & Agadjanyan M. Generation and characterization of the humoral immune response to DNA immunization with a chimeric β-amyloid-Interleukin-4 minigene. Eur J Immunol. 2003, 33(12), 3232-41.
38
Agadjanyan M.G., Ghochikyan A., Petrushina I.. Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T., Cribbs D.H. Prototype Alzheimer's disease vaccine utilizing the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope PADRE. J Immunol. 2005, 174 (3):1580-6.
39
Cribbs, D.H., Ghochikyan A., Vasilevko, V., Tran, M., Petrushina, I., Sadzikava, N., Babikyan D., Kieber-Emmons,T., Agadjanyan, M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid. Int. Immunol., 2003, 15 :505-14.
40
Petrushina I., Tran M., Sadzikava N., Ghochikyan A.,Vasilevko V., Cribbs H.D, and Agadjanyan G.M. Importance of detection of murine IgG2c antibodies in APP/Tg 2576 mice immunized with human β-amyloid peptide. Neuroscience Letters. 2003, 338(1):5-8.
Conference presentations
1
Zagorski K, King O, Hovakimyan A, Antonyan T, Petrushina I, Chadarevian JP, Danhash E, Cribbs DH, Davtyan H, Blurton-Jones M, Agadjanyan MG,Ghochikyan A. The first MultiTEP-based conjugated vaccine targeting pyroglutamated pE3Aβ is immunogenic and effective in 5xFAD animal model. Alzheimer's Association International Conference (AAIC), Denver, USA, July 26-30, 2021.
2
Chailyan G, Hovakimyan A,Antonyan T, Shabestari SK, Petrushina I, Coburn MA, Cribbs DH, Blum D, Buee L, Blurton-Jones M, Agadjanyan MG, Ghochikyan A, Davtyan H. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of Tau: therapeutic efficacy in PS19. 14th​ International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD), 2019, March26-31, Lisbon, Portugal.
3
Ghochikyan A, Davtyan H, Chailyan G, Hovakimyan A,Coburn MA, Petrushina I, Shabestari SK, Antonyan T, Blum D, Buée L, Cribbs DH, Blurton-Jones M, Agadjanyan MG. Alzheimer’s disease AdvaxCpG-adjuvanted MultiTEP-based vaccines reduce Ab and tau pathology in double transgenic mice. 14th​ International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD), 2019, March26-31, Lisbon, Portugal.
4
Ghochikyan A. Immunotherapeutic strategies for Alzheimer’s disease: targeting N-terminus of pathological tau.Society for Brain Mapping and Therapeutics (SBMT) Alzheimer’s Disease Conference 2018. Los Angeles, April 13-15, 2018.
5
Agadjanyan M.G., Petrovsky N., Ghochikyan A. Preventive Immunotherapy Strategy: Combining Aβ vaccine with adjuvants inducing pro-inflammatory or anti-inflammatory immune responses. Alzheimer's Association International Conference (AAIC), London, July 16-20, 2017.
6
Ghochikyan A., Zagorski K., Kazarian K., Davtyan H., Petrushina I., Davis J., Chen W., Antonenko M., Blurton-Jones M., Cribbs D.H., Agadjanyan M.G. Humanized mAb, Armanezumab targeting N-terminus of pathological tau: characterization and therapeutic potency. Alzheimer's Association International Conference (AAIC), Toronto, Canada, July 24-28, 2016.
7
Amado A.J. Davtyan H., Serraneau K., Zagorski K., Gordon M. N., Cribbs D.H. Ghochikyan A., Petrovsky N., Agadjanyan M. G., Morgan D.Active immunization with highly immunogenic tau epitope induced a strong immune response together with improvement in short memory but failed to significantly reduce tau pathology in a mouse model of tauopathy. Neuroscience, Chicago, IL, October 17-21, 2015.
8
Davtyan H., Petrushina I., Evans C.F., Hovakimyan A., Davtyan A., Hannaman D., Cribbs D.H., Ghochikyan A., Agadjanyan M.G. MultiTEP platform based AD vaccine immunogenic in rabbits and monkeys. Clinical Trials on Alzheimer’s Disease (CTAD), San Diego, CA, November 14-16, 2013.
9
Ghochikyan A., Davtyan H., Petrushina I., Hovakimyan A., Davtyan A., Movsesyan N., Kiyatkin A., Hannaman D., Evans C.F., Cribbs D.H., Agadjanyan M.G. Refinement of Alzheimer’s Disease DNA-based epitope vaccine: broad coverage of MHC polymorphism and targeting pre-existing memory T cells. 11th International Conference AD/PD, Florence, Italy, March 6-10, 2013.
10
Davtyan A., Ghochikyan A., Hovakimyan A., Davtyan H., Poghosyan A., Bagaev A., Ataullakhanov R.I., Nelson E.L., Agadjanyan M.G. Primary breast 4T1 tumor resection model for the testing for anti-cancer therapeutics. X Immunology Fair, UCI, Irvine, CA, November 15-16, 2012.
11
Davtyan H., Ghochikyan A., Petrushina I., Hovakimyan A., MovsesyanN., Kiyatkin A., Evans C., Hannaman D., Cribbs D.H., Agadjanyan M.G. Translational study: refinement of DNA based Alzheimer's disease (AD) epitope vaccine in rabbits. Alzheimer's Association International Conference (AAIC), Vancouver, Canada, July 14-19, 2012.
12
Davtyan H., Ghochikyan A., Petrushina I., Hovakimyan A., Davtyan A., Poghosyan A., Cribbs D.H., Agadjanyan M.G. Multiple approaches to immunotherapy against Alzheimer’s disease. "Brain Waves" Alz Symposium, Santa Barbara, April 19, 2012.
13
Davtyan H., Ghochikyan A., Albrecht R.A., MovsesyanN., Petrushina I., CribbsD.H., García-Sastre A., Agadjanyan M.G. The novel strategy for generation of effctive and safe Alzheimer's disease vaccine based on conventional Influenza virus vaccine modified to express Aβ1-10. 10th International Conference AD/PD, Barcelona, Spain, March 6-10, 2011.
14
Davtyan H., Mkrtichyan M., Movsesyan N., Petrushina I., Mamikonyan G., Cribbs D.H. Agadjanyan M.G., Ghochikyan A. Improvement of Alzheimer’s Disease (AD) DNA vaccine efficacy by DNA prime/protein boost regimen in mice and rabbitsDNA Vaccine International Conference. New Orleans, USA, March 2-4, 2010.
15
Mkrtichyan M., Khlghatyan J., Loukinov D., Movsesyan N., Davtyan H., Ghochikyan A. Agadjanyan M.G. DNA vaccine based on cancer-testis antigen, BORIS and IL21 molecular adjuvant is extremely effective for treatment of metastatic disease. DNA Vaccine International Conference. New Orleans, USA, March 2-4, 2010.
16
Ghochikyan A., Davtyan H., Movsesyan N., Mkrtichyan M., Petrushina I., Cribbs D.H., Agadjanyan M.G. Induction of rapid and robust anti-Aβ antibody production by reactivation of pre-existing memory Th cells generated from conventional vaccines. Presentation on the International Conference on Alzheimer’s Disease. Vienna, Austria, July 11-16, 2009.
17
Ghochikyan, A., PhD, Davtyan, H., PhD, Movsesyan, N., PhD, Mkrtichyan, M., PhD; Petrushina, I. Ph.D., Cribbs, D. H., PhD., Agadjanyan, M.G., PhD. Third  generation epitope vaccine (EV): A new Strategy for Ab immunotherapy. 9th International Conference AD/PD, Prague, Czech Republic, March 11-15, 2009.
18
Ghochikyan A., Martinez L., Movsesyan N., Mkrtichyan M., Petrushina I., Davtyan H., Cribbs D.H., García-Sastre A., Agadjanyan M.G.The novel strategy for generation of effective and safe Alzheimer’s Disease vaccine based on conventional influenza virus vaccine modified to express Aβ1-11. International Conference on Prevention of Dementia. Chicago, IL, 2008.
19
Ghochikyan, A., Movsesyan, N., Mkrtichyan, M., Petrushina, I., Arya Biragyn, Cribbs, D. H., Agadjanyan, M.G. DNA epitope vaccine prevents AD like pathology in 3xTg-AD mice and protects them from cognitive decline. International Conference on Prevention of Dementia. Washington, DC, June 9-12, 2007.
20
Ghochikyan, A., Movsesyan, N., Mkrtichyan, M., Petrushina, I., Biragyn, A., Cribbs, D. H., Agadjanyan, M.G. DNA epitope vaccine induced strong anti-Ab antibodies inhibiting AD like pathology in 3xTg-AD mice and protecting them from cognitive decline. 8th International Conference AD/PD, Salzburg, Austria, March 14-18, 2007.
21
Ghochikyan A., Movsesyan N., Mkrtichyan M., Mamikonyan G., Petrushina I., Cribbs, D. H., Agadjanyan, M.G. DNA-based AD epitope vaccine induced therapeutically potent anti-Ab antibodies in AD mouse model. Presentation on the 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain, July 14-21, 2006.
22
Ghochikyan A.,Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Oddo S., LaFerla F., Cribbs D. H., Agadjanyan M. G. Peptide epitope vaccine for A immunotherapy. Presentation on the 10th National Symposium: Basic Aspects of Vaccines. Bethesda, April 28-30, 2004.
23
Cribbs D., Lees A., Vasilevko V., Ghochikyan A., Petrushina I., Movsesyan N., Agadjanyan M. Alternative strategies for Aβ Immunotherapy using Active Immunization.12th International Congress of Immunology and 4th Annual Conference on FOCIS.
24
Cribbs D.H., Lees A., Ghochikyan A., Vasilevko V., Petrushina I., Babikyan D., Movsesyan N., Tran M., DeVolger A. and Agadjanyan M.G. Mannan as a Molecular Adjuvant for Ab- Immunotherapy. Publication of the Proceedings of the 6th International Conference on Progress in Alzheimer's and Parkinson's Disease AP / DP (Seville, Spain, May 8-12, 2003).
25
Ghochikyan A.,Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Oddo S., LaFerla F., Cribbs D. H., Agadjanyan M. G. Peptide epitope vaccine for A immunotherapy. Presentation on the 10th National Symposium: Basic Aspects of Vaccines. Bethesda, April 28-30, 2004.
26
Gevorkian G., Petrushina I., Ghochikyan A., Manoutcharian K.G., Acero G., Cribbs D.H., and Agadjanyan M.G. Anti-Aβ polyclonal sera from wildtype mice recognized predominantly EFRH epitope. Publication of the Proceedings of the 6th International Conference on Progress in Alzheimer's and Parkinson's Disease AP/DP (Seville, Spain,May 8-12, 2003).
27
Vasilevko, V., Tran, M., Petrushina, I., Ghochikyan, A., Kieber-Emmons, T., Agadjanyan, M.G., Cribbs, D.H. The role of adjuvant in the humoral and cellular immune responses to immunization with β-amyloid. Presentation on the 8th National Symposium: Basic Aspects of Vaccines. Bethesda, May 1-3, 2002
28
Ghochikyan, A., Petrushina, I., Tran, M., Sadzikava, N., Vasilevko, V., Cribbs, D.H., and Agadjanyan, M.G. Immunization of wildtype and APP/Tg animals with fibrillar Aβ42 induces antibodies to conformational antigenic determinants. Presentation on the Eighth National Symposium: Basic Aspects of Vaccines. Bethesda, May 1-3, 2002.
29
Ghochikyan, A.,  Cribbs, D.H., Agadjanyan, M.G. Different approaches to the development of vaccine against animal model of Alzhimer’s disease. Presentation on the 8th International Conference on Alzheimer’s Disease and Related Disorders.Stockholm, Sweden, 2002.
30
Cribbs, D.H., Ghochikyan, A., Tran, M., Vasilevko, V., Petrushina, I., Sadzikava, N., Patrick Kesslak, Kieber-Emmons, T., Agadjanyan, M.G. Detection of conformational antigenic determinant in wildtype & APP/TG mice immunized with Aβ42 peptide. Presentation on the 8th International Conference on Alzheimer’s Disease and Related Disorders.Stockholm, Sweden, 2002.
© 2022 Nuravax